Novartis (NVS) Q2 2026 earnings review
Growth Returns as Priority Brands Overpower the Patent Cliff
Novartis has officially entered the second phase of its 'year of two halves'. After generic competition for mega-blockbuster Entresto dragged sales into negative territory in Q1, Q2 saw a Reversing trend with top-line growth returning to +3% (+1% constant currency). The replacement power of the portfolio is working: massive gains in Kisqali, Kesimpta, and Scemblix offset the devastating >50% declines in genericized legacy brands. However, the volume swap comes with a cost—Core Operating Margin contracted 100 bps as favorable product mix evaporated. Furthermore, a spike in interest expense (funding the $12B Avidity acquisition) and higher tax rates caused a severe 19% drop in Net Income. Full-year guidance was reaffirmed, implying an Accelerating H2 to meet the target.
🐂 Bull Case
Priority brands are easily absorbing the loss of Entresto. Kisqali (+44%), Scemblix (+89%), and Pluvicto (+43%) added over $900M in incremental quarterly revenue, proving the commercial infrastructure is highly effective.
Core Operating Income flatlined (0%) this quarter, Reversing the brutal 14% contraction seen in Q1. The base effects of the generic launches are normalizing, paving the way for an Accelerating second half.
🐻 Bear Case
Replacing a mature, ultra-high-margin primary care drug (Entresto) with early-launch assets and heavily rebated specialty drugs is compressing margins. Core operating margin fell from 42.2% to 41.2% YoY.
Net income fell 19% as interest expenses surged by 60% (to $462M) to finance M&A, combined with a much higher effective tax rate (23.7% vs 11.2%). This severely dilutes the benefit of top-line stabilization.
⚖️ Verdict: ⚪
Neutral leaning Bullish. The commercial execution on the growth portfolio is undeniably strong, successfully navigating the company's largest historical patent cliff. However, the profit quality is currently strained by debt service and margin mix, requiring flawless pipeline execution in H2 to reignite earnings growth.
Key Themes
The 'Replacement Power' Thesis Validated
Management's core strategy of offsetting the Entresto/Promacta cliff with five priority brands is working. Kisqali surged to $1.69B (+44%), Kesimpta hit $1.42B (+32%), and Pluvicto demonstrated robust pre-taxane demand at $651M (+43%). This high-octane growth successfully masked the $1.1B combined quarterly revenue hole left by Entresto and Promacta generics.
Gross Margin & Profitability Compression
While the top-line narrative is positive, the underlying profit engine is sputtering. Gross profit declined 2% (USD) despite 3% revenue growth, reflecting unfavorable product mix as high-margin legacy revenues vanish. Consequently, Core Operating Margin Decelerated by 100 bps to 41.2%. Total core adjustments spiked to $1.2B, driven by higher restructuring and impairment charges.
Legacy Cliff Sapping the Bottom Line
The generic erosion is severe and unrelenting. Entresto plummeted 50% to $1.18B, Promacta fell 64% to $179M, and Tasigna dropped 57% to $142M. Furthermore, Xolair joined the laggards, declining 23% to $342M due to mounting biosimilar pressure. These legacy cash cows are drying up exactly as expected, testing the resilience of the broader portfolio.
Macro Headwinds: Cosentyx Struggles in China
Cosentyx grew 12% globally, buoyed by US performance in hidradenitis suppurativa (HS) and IV indications. However, management explicitly flagged that this growth was partially offset by a decline in China. This confirms concerns raised in previous quarters regarding a structural slowdown and intense pricing/competitive pressures in the Chinese market, which limits the ceiling for ex-US expansion.
Aggressive M&A Integration and Debt Expansion
The $12B acquisition of Avidity Biosciences closed in February, driving a massive increase in net debt from $21.9B to $39.4B. The debt service is now a material headwind (interest expense rose 60% to $462M). However, this M&A secures a highly strategic RNA therapeutics pipeline (DM1, FSHD, DMD) that provides the long-term growth engine post-2028.
Pipeline Delivering Key Regulatory Catalysts
R&D momentum remains strong. Kisqali presented 6-year follow-up data showing clinically meaningful overall survival in early breast cancer (eBC) and secured pediatric exclusivity (+6 months to all patents). Rhapsido achieved EC and Japan approvals for CSU, and Itvisma secured EC approval for a broad SMA patient population. These regulatory wins de-risk the mid-term growth trajectory.
Other KPIs
Decelerating. FCF dropped 9% YoY from $9.72B in H1 2025. This was driven primarily by lower net cash flows from operating activities resulting from lower net income and unfavorable changes in other financial receipts. The reduced cash flow coincides with a period of high debt servicing.
Despite a massive portfolio transition and multiple active launches, Core SG&A expenses only rose 6% YoY. Management cites 'productivity' as the driver, indicating strong cost discipline to protect the operating margin from compressing further than the 100 bps observed.
A massive spike from 11.2% in Q2 2025. Negatively impacted by the tax effects of an intercompany transaction and changes in uncertain tax positions. Even excluding these one-offs, the underlying rate increased to 17.3% due to a geographic shift in profit mix. This is a material headwind to EPS.
Guidance
Accelerating. With H1 2026 coming in at -2% cc (-1% USD) and Q2 specifically at +1% cc (+3% USD), maintaining this full-year guidance strictly requires the promised 'strong H2 rebound' to materialize, relying heavily on Kisqali eBC and Pluvicto momentum.
Accelerating. H1 Core OpInc was down 7% cc. Guiding for only a low single-digit decline for the full year implies a significant positive swing (growth) in the second half of 2026. This bakes in the planned 1-2% margin dilution from the Avidity acquisition, meaning underlying H2 operations must perform exceptionally well.
Key Questions
Margin Progression in H2
With Core Operating Margin down 100 bps in Q2 due to unfavorable product mix, and Avidity dilution now fully in the run-rate, what specific SG&A or cost-of-goods levers will be pulled to achieve the implied Core OpInc acceleration in H2?
Rhapsido Commercial Ramp
Rhapsido generated $64M this quarter, heavily supported by a free drug program in the US. What is the expected timeline and conversion rate for moving these patients onto paid scripts, and how will this impact gross-to-nets in late 2026?
Cosentyx China Strategy
You noted that Cosentyx's global growth was offset by a decline in China. Is this a temporary inventory dynamic, a result of NRDL pricing pressure, or a permanent structural shift due to domestic competition?
Entresto Floor
Entresto sales halved this quarter under generic pressure. Based on your modeling and historical analogs (like Diovan), at what point in 2027 do you expect the Entresto erosion curve to flatten and establish a stable tail?